Invitation to an Extraordinary General Meeting of Alcon, Inc. __________________________ Monday

General Meeting of Alcon, Inc.

__________________________

August 16, 2010, 10:00 a.m. (doors open at 9:00 a.m.)

Center Metalli at the Parkhotel Zug, CH-6304 Zug, Switzerland

elections to the Board of Directors (Conditional Resolution)

On behalf of our Board of Directors, we

would like to invite you to an Extraordinary General Meeting of Shareholders of

Alcon, Inc. to be held at the Congress Center Metalli, Zug, Switzerland, on

Monday, August 16, 2010. The elections of new members to the Board of

Directors are proposed for approval at the meeting. The agenda and

related information are set out below. The resolution to be taken at this

Extraordinary General Meeting of Shareholders of Alcon, Inc. shall become

effective only upon the consummation of the acquisition by Novartis AG of all

common shares of Alcon, Inc., with a par value of CHF 0.20 per share, that are

beneficially owned by Nestl S.A. as of such time, pursuant to the Purchase and

Option Agreement dated April 6, 2008 between Novartis AG and Nestl S.A., as

evidenced by a press release from Alcon, Inc.

Your vote is important. If

you are a registered holder, please vote now by proxy so that your shares are

represented at the meeting. You can vote your shares by marking your

choices on the enclosed proxy card, and then signing, dating and mailing it in

the enclosed envelope or by following the Internet or telephone voting

instructions on the proxy card. Using any of these methods, you

authorize Alcon, Inc. to vote your shares as you specified. If you

authorize Alcon, Inc. to vote your shares without giving any instructions, your

shares will be voted in accordance with the proposals of the Board of Directors

with regard to the item listed on the agenda. If new proposals (other

than the one on the agenda) are being put forth before the meeting, the Alcon,

Inc. representative will vote your shares in accordance with the position of the

Board of Directors. Proxy forms must be sent to the Company in the

enclosed envelope, arriving no later than August 11.

If you are a registered holder, you may

also authorize the inde pendent representative, Ms. Andrea Hodel,

Attorney-At-Law, Zug, Swit zerland, with full rights of substitution, to

vote your shares on your behalf. Ms. Hodel's address

is: Industriestrasse 13c, CH-6304 Zug, Switzerland. If you

authorize the independent representative to vote your shares without giving

instructions, your shares will be voted in accordance with the proposals of the

Board of Directors with regard to the item listed on the agenda. If

new proposals (other than the one on the agenda) are being put forth before the

meeting, the independent representative will abstain from voting your shares

with regards to any such new proposals. Proxy forms authorizing the

independent representative to vote your shares on your behalf must be sent to

the Company in the enclosed envelope or directly to the independent

representative, arriving no later than August 11.

Alternatively, if you are a registered

holder, you may choose to attend the meet ing and vote in person, or appoint

a proxy of your choice to vote at the meeting for you. The proxy need

not be a shareholder. If you choose to attend the meeting in person,

or appoint a proxy to attend on your behalf, your shares can only be voted at

the meeting. To select one of these options, please complete the

attendance portion of the enclosed proxy card and return it to the

Company in the enclosed envelope, arriving no later than August 11.

If you are a beneficial owner, you are

requested to instruct your broker or custodian as to how to vote your shares

using the instruction form provided to you. You may also instruct

your broker or custodian to authorize the independent representative to vote

your shares. Alternatively, if you wish to vote in person then you

Each holder wishing to attend the

meeting in person must present his/her admission card before 9:45 a.m. on August

16, 2010, at one of the control offices at the meeting location for

validation. Doors open at 9:00 a.m. Registered shareholders who have

appointed Alcon, Inc. or the independent representative as a proxy and

beneficial owners who have not obtained a power of attorney from their broker or

custodian may not attend the meeting in person or send an alternate proxy of

their choice to represent them at the meeting.

Please note that shareholders who have

sold their shares before the meeting date are not entitled to vote or

participate in the meeting.

shares of Alcon, Inc. are listed on the New York Stock Exchange (NYSE) under the

Inc., B sch 69, P.O. Box 62, CH-6331

additional information about Alcon, Inc., please contact Alcon Investor

Relations, 6201 South Freeway, MCT7-5, Fort Worth, Texas, 76134-2099, Telephone

(800) 400-8599, E-mail investor.relations@alconlabs.com or visit our web site at

Elections to the Board of Directors (Conditional Resolution)

The Board of Directors proposes that the

following persons be elected for the following terms of office:

resolution on the elections to the Board of Directors shall become effective

only upon the consummation of the acquisition by Novartis AG of all common

shares of Alcon, Inc., with a par value of CHF 0.20 per share, that are

beneficially owned by Nestl S.A. as of such time, pursuant to the Purchase and

Option Agreement dated April 6, 2008 between Novartis AG and Nestl S.A., as

evidenced by a press release from Alcon, Inc. (hereinafter referred to as the

following members of the Board of Directors have conditionally declared their

resignation, which resignation will be effective only upon occurrence of the

Condition: Werner Bauer, Francisco Casta er, Paul Bulcke, James Singh, Hermann

of Directors proposes that the following persons be elected to the Board of

Directors (which election will be effective upon occurrence of the

Vanni. Enrico Vanni (59) is a chemical engineer graduated from

the Federal Polytechnic School of Lausanne, Switzerland and holds a PhD

(Doctorate in Science) from the University of Lausanne. His

background also includes an MBA from INSEAD in Fontainebleau,

France. Enrico Vanni started his career in 1977 with IBM in San Jose,

California, and after his MBA in 1980, joined McKinsey & Company in Zurich,

Switzerland. He managed the Geneva Office from 1988 to

2004. His consulting activities mostly covered companies in the

pharmaceutical, consumer and finance sectors. He was head of the

European pharmaceutical practice and served as member of the Partner review

committee of the firm over many years. He retired as Director of

McKinsey at the end of 2007. Since 2008, he is an independent